Related Experiment Video

Updated: Mar 2, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential

Bharath K Velmurugan1, Chien-Hung Lee2,3, Shang-Lun Chiang4,5

  • 1Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam.

Journal of Cellular Physiology
|May 19, 2017
PubMed

Insights

Protein phosphatase 2A (PP2A) deactivation, marked by tyrosine-307 hyperphosphorylation, is common in oral cancer. Restoring PP2A with FTY720 may offer a therapeutic strategy for oral squamous cell carcinoma (OSCC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Protein phosphatase 2A (PP2A) acts as a tumor suppressor, frequently deactivated in various cancers.
  • The specific role and clinical significance of PP2A in oral squamous cell carcinoma (OSCC) are not well-established.

Purpose of the Study:

  • To investigate the deactivation mechanisms of PP2A in oral cancer.
  • To evaluate the clinical relevance of PP2A phosphorylation in OSCC patient outcomes.
  • To explore FTY720 as a potential therapeutic agent for OSCC.

Main Methods:

  • Assessed PP2A deactivation in oral cancer cells, focusing on tyrosine-307 (Y307) phosphorylation.
  • Treated cells with FTY720 to restore PP2A activity and monitored cell growth and downstream signaling (GSK-3β phosphorylation).
  • Analyzed PP2A phosphorylation levels in 262 OSCC tissue samples and correlated findings with clinical staging and patient survival.

Main Results:

  • PP2A deactivation via Y307 hyperphosphorylation is prevalent in oral cancer cells.
  • FTY720 treatment reactivated PP2A, inhibited cell growth, and reduced GSK-3β phosphorylation.
  • Elevated p-PP2A expression in tumors correlated with advanced N2/N3 stage and poorer overall survival, particularly in cases with lymph node metastasis.
  • High p-PP2A expression was a significant predictor of mortality density and reduced 10-year survival.

Conclusions:

  • PP2A deactivation is a frequent event in oral cancer, linked to poor prognosis.
  • Restoring PP2A function using FTY720 presents a potential therapeutic avenue for OSCC treatment.
Keywords:
Calyculin-AFTY720GSK-3βOSCCPP2Alymphnode metastasis

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K